IL128870A0 - Pharmaceutical compositions for treating fungal infections - Google Patents

Pharmaceutical compositions for treating fungal infections

Info

Publication number: IL128870A0
Authority: IL; Israel
Prior art keywords: inhibitors; antifungal; combination; xmp; polyenes
Prior art date: 1996-09-12

Application number

IL12887097A

Other languages

English (en)

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-12

Filing date

1997-09-09

Publication date

2000-06-01

1996-10-04 Priority claimed from GBGB9620739.4A external-priority patent/GB9620739D0/en

1997-09-09 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

2000-06-01 Publication of IL128870A0 publication Critical patent/IL128870A0/xx

Links

206010017533 Fungal infection Diseases 0.000 title 1
208000031888 Mycoses Diseases 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
229940121375 antifungal agent Drugs 0.000 abstract 5
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 abstract 3
239000003429 antifungal agent Substances 0.000 abstract 3
239000003112 inhibitor Substances 0.000 abstract 3
OXVVQYCKEAJWFA-QVCGFCSKSA-N 10,12-dimethyl-tetradecanoic acid [3-(3-amino-1-hydroxy-propyl)-6-[1,2-dihydroxy-2-(4-hydroxy-phenyl)-ethyl]-11,20,21,25-tetrahydroxy-15-(1-hydroxy-ethyl)-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexaaza-tricyclo[22.3.0.09,13]heptacos-18-yl]-amide Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCCC(C)CC(C)CC)[C@H](O)CCN)=CC=C(O)C=C1 OXVVQYCKEAJWFA-QVCGFCSKSA-N 0.000 abstract 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 abstract 2
229960003942 amphotericin b Drugs 0.000 abstract 2
230000000843 anti-fungal effect Effects 0.000 abstract 2
150000003851 azoles Chemical class 0.000 abstract 2
238000002648 combination therapy Methods 0.000 abstract 2
150000004291 polyenes Chemical class 0.000 abstract 2
PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 abstract 1
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 abstract 1
WWJFFVUVFNBJTN-UIBIZFFUSA-N (2S)-2-[[(2S,3S,4S)-2-amino-4-hydroxy-4-(5-hydroxypyridin-2-yl)-3-methylbutanoyl]amino]-2-[(2R,3S,4S,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]acetic acid Chemical class C[C@@H]([C@H](N)C(=O)N[C@@H]([C@H]1O[C@H]([C@@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O)C(O)=O)[C@H](O)c1ccc(O)cn1 WWJFFVUVFNBJTN-UIBIZFFUSA-N 0.000 abstract 1
VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 abstract 1
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 abstract 1
229920002101 Chitin Polymers 0.000 abstract 1
229940123047 Elongation factor inhibitor Drugs 0.000 abstract 1
229920000057 Mannan Polymers 0.000 abstract 1
BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 abstract 1
229930184499 Nikkomycin Natural products 0.000 abstract 1
229930182764 Polyoxin Natural products 0.000 abstract 1
229940098178 ambisome Drugs 0.000 abstract 1
230000000844 anti-bacterial effect Effects 0.000 abstract 1
150000001720 carbohydrates Chemical class 0.000 abstract 1
229960004884 fluconazole Drugs 0.000 abstract 1
RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 abstract 1
XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 abstract 1
229960004413 flucytosine Drugs 0.000 abstract 1
230000001939 inductive effect Effects 0.000 abstract 1
229960004130 itraconazole Drugs 0.000 abstract 1
229960004125 ketoconazole Drugs 0.000 abstract 1
150000002632 lipids Chemical group 0.000 abstract 1
229960002509 miconazole Drugs 0.000 abstract 1
WWJFFVUVFNBJTN-UHFFFAOYSA-N neopolyoxin C Natural products C=1C=C(O)C=NC=1C(O)C(C)C(N)C(=O)NC(C(O)=O)C(C(C1O)O)OC1N1C=CC(=O)NC1=O WWJFFVUVFNBJTN-UHFFFAOYSA-N 0.000 abstract 1
WWJFFVUVFNBJTN-VHDFTHOZSA-N nikkomycin Z Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)[C@H](NC(=O)[C@@H](N)[C@H](C)[C@H](O)C=2N=CC(O)=CC=2)C(O)=O)C=CC(=O)NC1=O WWJFFVUVFNBJTN-VHDFTHOZSA-N 0.000 abstract 1
-1 nikkomycins Natural products 0.000 abstract 1
229960000988 nystatin Drugs 0.000 abstract 1
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 abstract 1
230000035699 permeability Effects 0.000 abstract 1
229960001589 posaconazole Drugs 0.000 abstract 1
RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
239000002213 purine nucleotide Substances 0.000 abstract 1
239000002719 pyrimidine nucleotide Substances 0.000 abstract 1
150000003230 pyrimidines Chemical class 0.000 abstract 1
OPAHEYNNJWPQPX-RCDICMHDSA-N ravuconazole Chemical compound C=1SC([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=1C1=CC=C(C#N)C=C1 OPAHEYNNJWPQPX-RCDICMHDSA-N 0.000 abstract 1
OGGVRVMISBQNMQ-MDGIRFSOSA-N sordarin Chemical compound O[C@H]1[C@H](O)[C@H](OC)[C@@H](C)O[C@H]1OC[C@]1([C@@]2(C(C(C)C)=C3)C(O)=O)[C@H]3C[C@]2(C=O)[C@@H]2CC[C@@H](C)[C@H]2C1 OGGVRVMISBQNMQ-MDGIRFSOSA-N 0.000 abstract 1
OGGVRVMISBQNMQ-UHFFFAOYSA-N sordarin Natural products OC1C(O)C(OC)C(C)OC1OCC1(C2(C(C(C)C)=C3)C(O)=O)C3CC2(C=O)C2CCC(C)C2C1 OGGVRVMISBQNMQ-UHFFFAOYSA-N 0.000 abstract 1
BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 abstract 1
229960004740 voriconazole Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Marine Sciences & Fisheries (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IL12887097A 1996-09-12 1997-09-09 Pharmaceutical compositions for treating fungal infections IL128870A0 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US2632796P	1996-09-12	1996-09-12
GBGB9620739.4A GB9620739D0 (en)	1996-10-04	1996-10-04	Antifungal combination therapy
PCT/US1997/015987 WO1998010782A1 (fr)	1996-09-12	1997-09-09	Therapie antifongique combinee

Publications (1)

Publication Number	Publication Date
IL128870A0 true IL128870A0 (en)	2000-06-01

Family

ID=26310166

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL12887097A IL128870A0 (en)	1996-09-12	1997-09-09	Pharmaceutical compositions for treating fungal infections

Country Status (21)

Country	Link
EP (1)	EP0925070B1 (fr)
JP (1)	JP3288051B2 (fr)
KR (1)	KR100380871B1 (fr)
CN (1)	CN1235554A (fr)
AT (1)	ATE248625T1 (fr)
AU (1)	AU721334B2 (fr)
CA (1)	CA2265824C (fr)
CY (1)	CY2481B1 (fr)
CZ (1)	CZ88499A3 (fr)
DE (1)	DE69724626T2 (fr)
DK (1)	DK0925070T3 (fr)
EA (1)	EA002469B1 (fr)
EE (1)	EE03748B1 (fr)
ES (1)	ES2203819T3 (fr)
IL (1)	IL128870A0 (fr)
NO (1)	NO991207L (fr)
NZ (1)	NZ334446A (fr)
PL (1)	PL333282A1 (fr)
PT (1)	PT925070E (fr)
SK (1)	SK29999A3 (fr)
WO (1)	WO1998010782A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69512041T2 (de) *	1994-11-08	2000-02-03	Glaxo Wellcome S.A., Tres Cantos	Antifungale sordaridin-derivate
US6069126A (en) *	1996-09-12	2000-05-30	Merck & Co., Inc.	Antifungal combination therapy
AUPQ066399A0 (en) *	1999-05-31	1999-06-24	Fujisawa Pharmaceutical Co., Ltd.	Antifungal combination use
AUPQ462399A0 (en) *	1999-12-13	2000-01-13	Fujisawa Pharmaceutical Co., Ltd.	New use
KR100680464B1 (ko) *	2000-06-28	2007-02-08	주식회사 하이닉스반도체	반도체 소자의 캐패시터 제조 방법
JPWO2002098463A1 (ja) *	2001-06-05	2004-09-16	財団法人新産業創造研究機構	抗真菌組成物
NZ561675A (en) *	2005-04-07	2010-07-30	Toyama Chemical Co Ltd	Pharmaceutical composition and method using antifungal agent in combination
TWI385169B (zh)	2005-10-31	2013-02-11	Eisai R&D Man Co Ltd	經雜環取代之吡啶衍生物及含有彼之抗真菌劑
DK2070536T3 (da)	2006-10-06	2012-04-10	Toyama Chemical Co Ltd	Farmaceutisk sammensætning med et phenylamidin-derivat og fremgangsmåde til anvendelse af den farmaceutiske sammensætning i kombination med et antifungalt middel
TWI426918B (zh)	2007-02-12	2014-02-21	Merck Sharp & Dohme	Ｉｌ-２３拮抗劑於治療感染之用途
WO2009129525A2 (fr) *	2008-04-18	2009-10-22	Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Cellobio-oligosaccharides antifongiques et anti-carie produits par la dextransucrase
CN102274215B (zh) *	2010-06-10	2013-04-10	吉林大学	一种具有与氟康唑协同抗真菌作用的增效剂
CN102274217B (zh) *	2010-06-10	2013-04-10	吉林大学	三氯生作为抗真菌药物氟康唑增效剂的新用途
CN102274216B (zh) *	2010-06-10	2013-04-10	吉林大学	一种提高氟康唑抗真菌作用的增效剂
EP2636409A1 (fr)	2010-11-05	2013-09-11	Eisai R&D Management Co., Ltd.	Composition pharmaceutique combinée en tant qu'agent antifongique
CA2836131A1 (fr) *	2011-05-24	2012-11-29	Bayer Cropscience Lp	Combinaisons synergiques de fongicides de type polyene et de peptides non ribosomaux et procedes d'utilisation associes
CN102319326A (zh) *	2011-07-23	2012-01-18	李玮	一种治疗脚癣的浸药卫生纸
CN114052029A (zh) *	2021-11-25	2022-02-18	兰州大学	具哌嗪和哌啶骨架的医用化合物在防治植物真菌病害中的用途
CN115721633B (zh) *	2022-03-25	2024-05-03	山东大学	羟基茜草素在作为t3ss小分子抑制剂中的应用
CN116473985B (zh) *	2023-03-29	2024-12-10	暨南大学	一种多烯类抗真菌药物组合物及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5378804A (en) *	1993-03-16	1995-01-03	Merck & Co., Inc.	Aza cyclohexapeptide compounds

1997
- 1997-09-09 PL PL97333282A patent/PL333282A1/xx unknown
- 1997-09-09 CZ CZ99884A patent/CZ88499A3/cs unknown
- 1997-09-09 WO PCT/US1997/015987 patent/WO1998010782A1/fr not_active Ceased
- 1997-09-09 AU AU43392/97A patent/AU721334B2/en not_active Ceased
- 1997-09-09 EP EP97941495A patent/EP0925070B1/fr not_active Expired - Lifetime
- 1997-09-09 ES ES97941495T patent/ES2203819T3/es not_active Expired - Lifetime
- 1997-09-09 EA EA199900283A patent/EA002469B1/ru not_active IP Right Cessation
- 1997-09-09 NZ NZ334446A patent/NZ334446A/xx unknown
- 1997-09-09 DE DE69724626T patent/DE69724626T2/de not_active Expired - Lifetime
- 1997-09-09 CN CN97199420A patent/CN1235554A/zh active Pending
- 1997-09-09 EE EEP199900088A patent/EE03748B1/xx not_active IP Right Cessation
- 1997-09-09 KR KR10-1999-7002052A patent/KR100380871B1/ko not_active Expired - Fee Related
- 1997-09-09 PT PT97941495T patent/PT925070E/pt unknown
- 1997-09-09 IL IL12887097A patent/IL128870A0/xx unknown
- 1997-09-09 AT AT97941495T patent/ATE248625T1/de active
- 1997-09-09 DK DK97941495T patent/DK0925070T3/da active
- 1997-09-09 CA CA002265824A patent/CA2265824C/fr not_active Expired - Fee Related
- 1997-09-09 SK SK299-99A patent/SK29999A3/sk unknown
- 1997-09-09 JP JP51380898A patent/JP3288051B2/ja not_active Expired - Fee Related
1999
- 1999-03-11 NO NO991207A patent/NO991207L/no not_active Application Discontinuation
2004
- 2004-10-27 CY CY0400076A patent/CY2481B1/xx unknown

Also Published As

Publication number	Publication date
AU721334B2 (en)	2000-06-29
CA2265824A1 (fr)	1998-03-19
CY2481B1 (en)	2005-06-03
NZ334446A (en)	2000-11-24
KR100380871B1 (ko)	2003-04-18
NO991207D0 (no)	1999-03-11
PL333282A1 (en)	1999-11-22
EA199900283A1 (ru)	1999-08-26
JP3288051B2 (ja)	2002-06-04
DE69724626T2 (de)	2004-07-29
NO991207L (no)	1999-05-11
AU4339297A (en)	1998-04-02
PT925070E (pt)	2003-12-31
EP0925070B1 (fr)	2003-09-03
KR20000036054A (ko)	2000-06-26
CN1235554A (zh)	1999-11-17
SK29999A3 (en)	2000-02-14
CZ88499A3 (cs)	1999-10-13
CA2265824C (fr)	2004-11-09
DK0925070T3 (da)	2003-12-01
EE9900088A (et)	1999-10-15
ES2203819T3 (es)	2004-04-16
EP0925070A1 (fr)	1999-06-30
ATE248625T1 (de)	2003-09-15
WO1998010782A1 (fr)	1998-03-19
EA002469B1 (ru)	2002-06-27
JP2000503675A (ja)	2000-03-28
EE03748B1 (et)	2002-06-17
DE69724626D1 (de)	2003-10-09

Publication	Publication Date	Title
IL128870A0 (en)	2000-06-01	Pharmaceutical compositions for treating fungal infections
Galgiani	1990	Fluconazole, a new antifungal agent
WO2000072865A3 (fr)	2001-05-10	Utilisation combinee d'antifongiques
BR9916296A (pt)	2004-06-29	Método para tratamento de bronquite crÈnica severa (bronquiectase) com um antibiótico em forma de aerossol
US6069126A (en)	2000-05-30	Antifungal combination therapy
WO1995017165A3 (fr)	1995-07-20	Compositions anti-microbiennes d'humidification des tissus
Sugar et al.	1998	Interactions of itraconazole with amphotericin B in the treatment of murine invasive candidiasis
Polak	1989	Combination therapy for systemic mycosis
Luna et al.	2000	Agents for treatment of invasive fungal infections
BRPI0418623A (pt)	2007-05-29	composição farmacêutica, e, embalagem
Graybill	1988	Therapeutic agents
WO2001066551A8 (fr)	2003-06-26	Composes azole comme agents therapeutiques pour traiter des infections mycosiques
Clark et al.	2012	The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C
Shinohara et al.	1997	Successful use of boric acid to control azole-refractory Candida vaginitis in a woman with AIDS
HUP0000127A2 (hu)	2000-06-28	Több hatóanyagot tartalmazó antimikotikus kompozíció
KR20250102476A (ko)	2025-07-07	산화 아연 및 아졸계 화합물의 병용 요법을 이용한 피부 감염증의 치료 방법
MXPA99002401A (en)	1999-09-01	Antifungal combination therapy
Calandra et al.	2003	Response to van Saene et al.'s comment on" Prevention of severe Candida infections in non-neutropenic, high-risk, critically ill patients"
More et al.	0	A REVIEW OF STUDY OF ANTIFUNGAL AGENTS
CN1669554A (zh)	2005-09-21	脂质体活力康唑制剂
MXPA02007641A (es)	2004-04-02	Uso de farmaceutico de la combinacion de fluconazol-tinidazol y su composicion para la administracion oral.